In this context, ER antagonists such as fulvestrant and raloxifene, both of which are United States Food and Drug Administration approved for the treatment of human breast cancer, have shown promising effects in reducing cervical cancer progression in mouse models. This evidence concerns the gene ESR1 and cervical cancer.